home / stock / blrx / blrx news


BLRX News and Press, BioLineRx Ltd. From 08/06/20

Stock Information

Company Name: BioLineRx Ltd.
Stock Symbol: BLRX
Market: NASDAQ
Website: biolinerx.com

Menu

BLRX BLRX Quote BLRX Short BLRX News BLRX Articles BLRX Message Board
Get BLRX Alerts

News, Short Squeeze, Breakout and More Instantly...

BLRX - BioLineRx Reports Second Quarter 2020 Financial Results and Provides Corporate Update

TEL AVIV, Israel , Aug. 6, 2020 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, today reports its financial results for the quarter ended June 30, 2020 and provides a corporate update. Highlights and ...

BLRX - BioLineRx to Report Second Quarter 2020 Results on August 6, 2020

TEL AVIV, Israel , July 31, 2020 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, announced today it will release its unaudited financial results for the quarter ended June 30, 2020 on Thursday, A...

BLRX - BioLineRx slips 14% on launch of $4.4M direct offering

BioLineRx ( BLRX -13.9% ) has entered into definitive agreements with several institutional investors for the purchase and sale of 2,510,286 American Depositary Shares (ADSs), at a purchase price of $1.75/ADS, in a registered direct offering. Each ADS represents 15 ordinary sha...

BLRX - EVH, PFE among premarket losers

Edwards Lifesciences (NYSE: EW ) -66% . More news on: Edwards Lifesciences Corporation, Iterum Therapeutics plc, Novus Therapeutics, Inc., Stocks on the move, , Read more ...

BLRX - BioLineRx Announces $4.39 Million Registered Direct Offering

TEL AVIV, Israel , June 1, 2020 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, today announced that it has entered into definitive agreements with several healthcare-focused, institutional and accredite...

BLRX - BioLineRx Announces Publication of Data from Ongoing COMBAT/KEYNOTE-202 Clinical Trial in Nature Medicine

TEL AVIV, Israel , May 27, 2020 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical Company focused on oncology, today announced that a paper, entitled 'BL-8040, a CXCR4 Antagonist, in Combination with Pembrolizumab and Chemotherapy for Pancreati...

BLRX - LK, ALT, CLBS and BLRX among midday movers

Gainers:  Mmtec (NASDAQ: MTC )  +83% . More news on: Mmtec, Inc., Luckin Coffee Inc., Mitcham Industries, Inc., Stocks on the move, , Read more ...

BLRX - BioLineRx down 29% on launch of $9M direct offering

BioLineRx (NASDAQ: BLRX ) has entered into definitive agreements with several investors for the purchase and sale of 5,142,859 of the Company's American Depositary Shares (ADSs), at a purchase price of $1.75/ADS, in a registered direct offering, for expected gross proceeds of $9M. M...

BLRX - LTM, KMDA among premarket losers

LATAM Airlines Group (NYSE: LTM )  -41%  after filing for bankruptcy . More news on: LATAM Airlines Group S.A., BioLineRx Ltd., GigaMedia Limited, Stocks on the move, , Read more ...

BLRX - BioLineRx Announces $9.0 Million Registered Direct Offering

TEL AVIV, Israel , May 26, 2020 /PRNewswire/ -- BioLineRx Ltd. (Nasdaq: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, today announced that it has entered into definitive agreements with several healthcare-focused, institutional and accr...

Previous 10 Next 10